Juvenile idiopathic arthritis (JIA) is an autoimmune, rheumatologic disease characterized by joint inflammation, pain, and stiffness. JIA encompasses multiple forms of chronic arthritis in children. The JIA patient population is subdivided into several subpopulations that are distinguished by serologic and genetic markers and systemic manifestations. The burden of the disease can be exacerbated by progressive deterioration from the arthritis, which affects some patients for life. Current treatment options are disease-modifying antirheumatic drugs (DMARDs) and nonsteroidal anti-inflammatory drugs (NSAIDs), both of which aim to control pain, improve function, and reduce inflammation. However, agents with improved efficacy and a milder side-effect profile, to facilitate chronic therapy in particular, remain an unmet need in all JIA subpopulations.
Questions Answered in This Report:
- JIA is a pediatric disease primarily affecting children with an onset before the age of 16. What is the size of the U.S. and EU5 JIA patient populations, and how will they change through 2024? What are the key JIA subpopulations?
- Patients with JIA are often managed by multidisciplinary teams, and the treatment paradigm has evolved with the introduction of multiple biological DMARDs. What is the current medical practice for the treatment and management of JIA patients? How is experts’ understanding of JIA pathophysiology evolving?
- Biological DMARDs have dramatically improved treatment outcomes for patients with JIA, but several unmet needs remain, including treatment approaches tailored to specific JIA subtypes and greater awareness that young patients can suffer from this rheumatologic disease. What unmet needs are expected to remain unaddressed by JIA therapies currently in mid- to late-stage development? Which emerging therapies are likely to see use in JIA through 2014?
Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.
Primary research: Eight country-specific interviews with pediatric rheumatologists.
Epidemiology: Diagnosed incident cases of JIA, diagnosed prevalent cases of JIA including by subtype: psoriatic arthritis, enthesitis-related arthritis, systemic arthritis, polyarthritis rheumatoid factor-positive and rheumatoid factor-negative, oligoarticular arthritis, and undifferentiated.
Wouter van der Pluijm, MPH